Skip to content

Virtual screening and molecular docking of flavonoid compounds as BACE-1 inhibitors for Alzheimer's Disease: identification of Betagarin as a promising nutraceutical lead candidate.

Nov 2026 · Natural Product Research · pp. 1-11 · 0 citations · 16 references
Medicine

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder accounting for 60-70% of dementia cases globally, with the β-site amyloid precursor protein cleaving enzyme-1 (BACE-1) representing one of the most intensively studied therapeutic targets due to its rate-limiting role in amyloid-β (Aβ) peptide production. Despite decades of drug discovery efforts, no approved BACE-1 inhibitor has successfully demonstrated both efficacy and safety in large-scale clinical trials, largely owing to off-target toxicity and poor blood-brain barrier (BBB) permeability. This study presents a multi-tiered structure-based virtual screening of 1,870 flavonoid compounds against the catalytic domain of BACE-1 (PDB ID: 2ZJN) using AutoDock Vina. Ligand preparation was performed with Open Babel v3.1.1, and docking was executed within a 30 × 30 × 30 Å grid box centred on the catalytic aspartyl dyad (Asp32 and Asp228). Drug-likeness was evaluated using Lipinski's Rule of Five, and in silico toxicity was assessed via the OSIRIS Property Explorer across four risk categories. Betagarin, a natural flavonoid constituent of Beta vulgaris (beetroot), was selected as the primary lead candidate, demonstrating a binding affinity of -9.3 kcal/mol, zero Lipinski violations, a molecular weight of 328.316 Da, a LogP of 3.139, and uniformly low-risk toxicological predictions. These results collectively support Betagarin as a compelling nutraceutical-derived BACE-1 inhibitor with a favourable pharmacokinetic and safety profile. Future in vitro enzymatic assays and in vivo validation studies are warranted to confirm inhibitory efficacy and advance this compound towards preclinical development.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.